 NEWARK, Calif., Oct. 4, 2021 PRNewswire -- Protagonist Therapeutics, Inc. Nasdaq: PTGX Protagonist or the Company today announced that an abstract highlighting new results from its Phase 2 study of rusfertide in hereditary hemochromatosis HH has been selected for oral presentation at The Liver Meeting 2021, hosted by the American Association for the Study of Liver Diseases AASLD, taking place virtually November 12-15, 2021. 